financial results

Profit After Tax (PAT) for the quarter at Rs 131 crores grew by ~ 13 per cent

Biosimilars Up 54 per cent; Research services up 23 per cent; Generics up 18 per cent

Consolidated profit rose to Rs 1.24 billion ($15.22 million) for the three months ended 31st December, from Rs 1.01 billion a year…

The drug firm had reported a net profit of Rs 706 crore in the October-December period of the previous fiscal.

Its total revenue from operations rose to Rs 5,810 crore for the third quarter compared to Rs 5,479 in the year-ago period, Cipla…

Revenue up to Rs 803 crore, PAT up to Rs 110 crores

The American partner EyeC America contributed to this with an order intake above the €2 million mark

The total income from operation for the quarter ending September 2022 reported at Rs 146.30 crore, higher by 12.54 per cent over…

The total income stood at Rs 546 crore against Rs 570 crore QoQ and Rs 548 crore YoY

Operating revenue at Rs 452.6 crore, increased 25.5 per cent YoY, driven by a growth in the existing products as well as market…